Evidence map›Paper›PMID 29139030›Full record

ArticleClinical rheumatology2018

Potential risk factors for reactive arthritis and persistence of symptoms at 2 years: a case-control study with longitudinal follow-up.

Helga Raquel Garcia Ferrer, Alexander Azan, Isa Iraheta, Joan Von Feldt, Luis R Espinoza, Julia Manasson, Jose U Scher, Abraham Garcia Kutzbach, Alexis Ogdie

Abstract read
In one paragraph

Article in Clinical rheumatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Reactive arthritis: update 2018.Clinical rheumatology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Helga Raquel Garcia FerrerGuatemalan Association against Rheumatic Diseases (AGAR), Guatemala City, Guatemala.
Alexander AzanDivision of Rheumatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Isa IrahetaGuatemalan Association against Rheumatic Diseases (AGAR), Guatemala City, Guatemala.
Joan Von FeldtDivision of Rheumatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Luis R EspinozaLSU Health Science Center, New Orleans, LA, USA.
Julia ManassonNew York University School of Medicine, New York, NY, USA.
Jose U ScherNew York University School of Medicine, New York, NY, USA.
Abraham Garcia KutzbachGuatemalan Association against Rheumatic Diseases (AGAR), Guatemala City, Guatemala.
Alexis OgdieDivision of Rheumatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. alexis.ogdie@uphs.upenn.edu.ORCID http://orcid.org/0000-0002-4639-0775
University of Pennsylvania · USNew York University · USUniversidad Francisco Marroquín · GTLouisiana State University Health Sciences Center New Orleans · US

Funding

Translational Basic and Clinical Research Training in RheumatologyT32AR069515 · NIAMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Jill P Buyon, Jose U. Scher · 2017 to 2026
$2.9M
Chronic disease clinical epidemiology training in guatemala and peruD43TW008317 · FIC · UNIVERSITY OF PENNSYLVANIA · PI BRANAS, CHARLES C. · 2010 to 2014
$1.1M
Identification of Early Psoriatic ArthritisK23AR063764 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI OGDIE, ALEXIS R. · 2013 to 2017
$751k
The Role of Gut and Skin Microbiome in Psoriatic ArthritisK23AR064318 · NIAMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SCHER, JOSE U. · 2013 to 2016
$589k
FIC NIH HHS D43 TW008317Fogarty International Center D43TW008317National Institutes of Health K23 AR063764National Institutes of Health K23 AR064318NIAMS NIH HHS K23 AR063764NIAMS NIH HHS K23 AR064318NIAMS NIH HHS T32 AR069515
6 · The paper itself

Abstract

The objective of the study is to determine the risk factors for the development of reactive arthritis (ReA) and examine the factors associated with the persistence of symptoms. Patients with a new diagnosis of ReA and controls with a gastrointestinal (GI), urogenital, or sexually transmitted infection in the 3-6 months prior to study entry were prospectively enrolled in Guatemala City. ReA patients fulfilled the Assessment in Spondyloarthritis International Society criteria for peripheral spondyloarthropathy (SpA). Patients underwent history, examination, Achilles tendon ultrasound, and blood draw. Human leukocyte antigen (HLA) type and serum biomarkers were measured. t tests and nonparametric equivalents were used to examine the association of clinical, laboratory, and imaging factors with ReA. Patients were contacted 2 years later to assess for persistence of symptoms. Study subjects included patients with ReA (N = 32) and controls (N = 32). ReA patients were most frequently infected in April whereas controls were most frequently infected in August. Two ReA patients and two controls were HLA-B27-positive. Serum cathepsin K and C-reactive protein were higher in ReA patients compared to controls (p = 0.03 for both), while total cholesterol and low-density lipoprotein were lower (p = 0.008 and 0.045, respectively). Among those with ReA, 15 (47%) patients had continued symptoms at 2 years. These patients had a lower matrix metalloproteinase-3 level at diagnosis than patients for whom ReA resolved (p = 0.004). HLA-B27 was not associated with development of ReA in Guatemala; however, the month of infection was associated with ReA. The most striking finding was the persistence of arthritis at 2 years in nearly half of the patients.

Indexed as

AdolescentAdultArthritis, ReactiveBiomarkersCase-Control StudiesFemaleFollow-Up StudiesHLA-B27 AntigenHumansMaleMiddle AgedProhibitinsRisk FactorsSymptom AssessmentYoung AdultBiomarkersHLA-B27 AntigenPHB2 protein, humanProhibitinsBiomarkersEpidemiologyPrognosisReactive arthritisRisk factorsSpondyloarthropathy

Identifiers

PMID29139030
PMCPMC5776049
OpenAlexW2768318623

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.